The Generic Medicines Industry Association has welcomed the PBAC’s decision to consider “a” flagging of biosimilars, and to list biosimilar insulin (Basaglar) on the PBS.
Basaglar is the first biosimilar insulin to be approved in Australia, providing an alternative, affordable treatment option for patients suffering from diabetes.
“Australian patients are now able to benefit from more affordable biosimilars and, as a result of competition, the PBS savings expected to be generated from biosimilars can provide an opportunity to improve patient access to life-changing medications,” says GMiA CEO Belinda Wood.
“The availability, and PBS listing, of biosimilars means more patients can be treated within the same budget.
“However, savings can only be realised if more affordable biosimilars are listed on the PBS, prescribed by doctors and dispensed by pharmacists.
“GMiA welcomes the PBAC decision to consider the marking as equivalent, also known as ‘a’ flagging, of biosimilars and their reference products on a case-by-case basis,” said Ms. Wood
The decision to apply an “a” flag to a biosimilar in the Schedule of Pharmaceutical Benefits will enable a pharmacist to substitute the biosimilar for the reference biological medicine in exactly the same way as generic medicines.